Impact of serum soluble CD155 level at diagnosis on interim response to CHOP with or without rituximab in diffuse large B cell lymphoma

Azzazi, Mohamed; Hegab, Hany M.; El-Ghammaz, Amro Mohamed Sedky; Saber, Heba Gamal; Afifi, Y. A.

doi:10.1007/s10238-021-00741-9

Cited by 4 publications

(2 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two splice forms, lacking the transmembrane region, have also been described as soluble or secreted isoforms that seem to compete with the membrane-anchored ones ( 68 , 69 ). CD155 is highly expressed on CD11c + human dendritic cells (DCs) ( 70 , 71 ), macrophages ( 72 , 73 ), T ( 74 ) and B cells ( 75 ), epithelial cells ( 74 , 76 ), kidneys ( 76 ), nervous system ( 77 ), intestine ( 78 , 79 ), and tumor cells ( 80 , 81 ). In vivo , the CD155–TIGIT pathway suppresses immunological responses increasing IL-10 anti-inflammatory cytokine ( 82 , 83 ) and decreasing IL-12 pro-inflammatory cytokine released by DCs ( 46 , 84 ).…”

Section: Overview Of Tigit Structure and Ligandsmentioning

confidence: 99%

Update in TIGIT Immune-Checkpoint Role in Cancer

2022

View full text Add to dashboard Cite

The in-depth characterization of cross-talk between tumor cells and T cells in solid and hematological malignancies will have to be considered to develop new therapeutical strategies concerning the reactivation and maintenance of patient-specific antitumor responses within the patient tumor microenvironment. Activation of immune cells depends on a delicate balance between activating and inhibitory signals mediated by different receptors. T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) is an inhibitory receptor expressed by regulatory T cells (Tregs), activated T cells, and natural killer (NK) cells. TIGIT pathway regulates T cell-mediated tumor recognition in vivo and in vitro and represents an exciting target for checkpoint blockade immunotherapy. TIGIT blockade as monotherapy or in combination with other inhibitor receptors or drugs is emerging in clinical trials in patients with cancer. The purpose of this review is to update the role of TIGIT in cancer progression, looking at TIGIT pathways that are often upregulated in immune cells and at possible therapeutic strategies to avoid tumor aggressiveness, drug resistance, and treatment side effects. However, in the first part, we overviewed the role of immune checkpoints in immunoediting, the TIGIT structure and ligands, and summarized the key immune cells that express TIGIT.

show abstract

Section: Overview Of Tigit Structure and Ligandsmentioning

confidence: 99%

Update in TIGIT Immune-Checkpoint Role in Cancer

2022

View full text Add to dashboard Cite

show abstract

“…Serum soluble CD155 levels are significantly higher in patients with hepatocellular carcinoma than those in healthy donors, and these levels are positively correlated with tumor stage [ 12 ]. Serum soluble CD155 could be used as a predictive marker in the adjuvant diagnosis of diffuse large B-cell lymphoma [ 13 ]. Whether CD155 has significant changing in PE patients deserves further investigation.…”

Section: Introductionmentioning

confidence: 99%

Expression of the immune checkpoint molecules CD226 and TIGIT in preeclampsia patients

Li,

Liu,

Duan

2024

BMC Immunol

View full text Add to dashboard Cite

Background Imbalanced immune responses are involved in developing preeclampsia (PE). We wish to explore the expression and potential changes of immune checkpoint molecules TIGIT, CD226 and CD155 in PE patients. Methods The expression of the immune checkpoint molecules TIGIT, CD226 and CD155 in different lymphocyte subpopulations was determined by flow cytometry in 24 patients with PE and compared to 24 healthy pregnant women of the same gestational age as the controls.Serum CD155 was detected by ELISA in the patients with PE compared to controls. Results The percentages of CD4+ and CD8+ T lymphocytes in the peripheral blood of PE patients were not significantly different from those of the controls, whereas the regulatory T cells (Tregs) in PE patients were significantly lower than those in controls (6.43 ± 1.77% vs. 7.48 ± 1.71%, P = 0.0420). The expression of TIGIT and CD226 showed different percentages on CD4+ T cells, CD8+ T cells and Treg cells. However, the difference in the percentages of TIGIT, CD226 on these T cells between the two groups was not statistically significant. The level of CD155 in peripheral serum of PE patients was 6.64 ± 1.79 ng/ml, which was not significantly different from that in the control group 5.61 ± 1.77 ng/ml, P = 0.0505. The present results demonstrate that TIGIT, CD226 and CD155 are not present at altered immune conditions in the peripheral blood of patients with PE, compared with normal pregnant women. Conclusion The immune checkpoint molecules TIGIT, CD226 and CD155 are not abnormally expressed in PE patients.

show abstract

The Role of Soluble Immune Checkpoints in Cancer Immunotherapy

Huntington

El‐Deiry

2023

Handbook of Cancer and Immunology

View full text Add to dashboard Cite

Impact of serum soluble CD155 level at diagnosis on interim response to CHOP with or without rituximab in diffuse large B cell lymphoma

Cited by 4 publications

References 42 publications

Update in TIGIT Immune-Checkpoint Role in Cancer

Update in TIGIT Immune-Checkpoint Role in Cancer

Expression of the immune checkpoint molecules CD226 and TIGIT in preeclampsia patients

The Role of Soluble Immune Checkpoints in Cancer Immunotherapy

Contact Info

Product

Resources

About